iOmx Therapeutics raises EUR 40 million in Series A round led by MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures
by eazee-designstudio
Austrian biotech company Themis Bioscience said it had started a clinical trial of an experimental Zika vaccine in healthy volunteers.
Leading European research groups pool their expertise for the fast development of an effective and affordable vaccine against the Zika virus.
Themis Bioscience: Zika Vaccine Development Receives Big Boost by Innovate UK
To advance novel RIG-I targeted immuno-oncology therapeutics. The company also announced opening of Cambridge, MA office.
